Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22362933 | 0.84 | MEN1 (0.41) | MEN1MAPK1KMT2ABTKDPP8 | |
| SCHEMBL31527127 | 0.83 | MEN1 (0.42) | MEN1MAPK1KMT2ABTKNFKB1 | |
| SCHEMBL25492182 | 0.82 | MEN1 (0.34) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL25492269 | 0.82 | MEN1 (0.34) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL23833804 | 0.82 | MEN1 (0.34) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL25492257 | 0.82 | MEN1 (0.34) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL23833802 | 0.79 | MEN1 (0.33) | MEN1MAPK1KMT2A | |
| SCHEMBL23833789 | 0.79 | MEN1 (0.33) | MEN1MAPK1KMT2A | |
| SCHEMBL23833800 | 0.79 | MEN1 (0.33) | MEN1MAPK1KMT2A | |
| SCHEMBL23833798 | 0.79 | MEN1 (0.33) | MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158178-A1 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | UNIV EMORY (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4121121-A1 | RADIONUCLIDE TRACERS OF 1-AMINO-3,4-DIFLUOROCYCLOPENTANE-1-CARBOXYLIC ACID, DERIVATIVES, AND USES THEREOF | Emory University (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188592-A1 | RADIONUCLIDE TRACERS OF 1-AMINO-3,4-DIFLUOROCYCLOPENTANE-1-CARBOXYLIC ACID, DERIVATIVES, AND USES THEREOF | EMORY UNIVERSITY (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158178-A1 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | AFF1, METTL3, VHL | MEN1 790/4885MAPK1 3027/4885KMT2A 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.